Vasodilator Agents in Pediatric Cardiac Surgery with Cardiopulmonary Bypass

DURING THE LAST few decades, significant progress has occurred in the surgical management of congenital heart disease (CHD), which is performed regularly in tertiary hospitals worldwide. This progress has contributed to increased life expectancy, and since the advent of neonatal repair of complex lesions in the 1970s, an estimated 85% of patients survive into adult life.1 Moreover, to improve early postoperative recovery, the safest anesthetic management and correct choice of vasoactive drugs to facilitate weaning from cardiopulmonary bypass (CPB) are among the main challenges faced by anesthesiologists during these procedures.

Source: Journal of Cardiothoracic and Vascular Anesthesia - December 14, 2017 Category: Anesthesiology Authors: Gretel Oliveira Nicolau, Caetano Nigro Neto, Francisco Jos é Lucena Bezerra, Glaucio Furlanetto, Sávio Cavalcante Passos, Adriene Stahlschmidt Tags: Review Article Source Type: research